Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

European marketing application for Myotrophin withdrawn

Sep. 16, 1998

Algos releases phase III clinical trial results for MorphiDex

Sep. 16, 1998

Merck KGaA discovers potent dual 5-HT1A antagonist and 5-HT reuptake inhibitor

Sep. 16, 1998

S-23751: new 5-HT1A/5-HT7 receptor ligand with anxiolytic activity

Sep. 16, 1998

Potent and selective 5-HT1B/1D antagonists designed by Merck KGaA

Sep. 16, 1998

Arylsulfonamides as inhibitors of PLA2, cytokine release and neurodegeneration

Sep. 16, 1998

Wafer formulation of rizatriptan delivers fast and effective migraine relief

Sep. 16, 1998

First phase III MS results reported for Novantrone

Sep. 15, 1998

Cerebrus enters into collaborative agreement with Lilly for CEB-1555

Sep. 15, 1998

Scios will copromote SmithKline Beecham's SSRI

Sep. 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...